Total amount raised
$4.5 Billions
Latest funding date
1/1/2025
Location
Moderna has successfully raised significant funding through multiple rounds, attracting a diverse group of investors. The company is at the forefront of mRNA technology, developing innovative therapeutics and vaccines.
Keep reading to explore the intricacies of Moderna's fundraising journey and the investors backing this pioneering biotechnology company.
What Is Moderna?
Founded in 2010 in Cambridge, Massachusetts, Moderna is a biotechnology company specializing in mRNA therapeutics and vaccines. The company was established by Derrick Rossi, Kenneth Chien, Noubar Afeyan, and Robert Langer.
Moderna's innovative technology uses messenger RNA to instruct cells to produce proteins necessary for various biological functions, targeting areas such as genetic disorders, hemophilia, oncology, and infectious diseases.
With a workforce of 1001-5000 employees, Moderna continues to push the boundaries of medical science, aiming to deliver impactful mRNA medicines to improve global health.
How Much Funding Has Moderna Raised?
- Amount Raised: $8M
- Date: September 2016
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support early-stage research and development efforts.
- Amount Raised: $474M
- Date: August 2016
- Lead Investors: AstraZeneca
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand mRNA technology applications and scale up production capabilities.
- Amount Raised: $125M
- Date: May 2018
- Lead Investors: Merck KGaA
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance clinical trials for mRNA-based therapeutics.
- Amount Raised: $500M
- Date: February 2018
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate the development of a broad pipeline of mRNA medicines.
- Amount Raised: $483M
- Date: April 2020
- Lead Investors: Biomedical Advanced Research and Development Authority (BARDA)
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund the development of a COVID-19 vaccine.
- Amount Raised: $472M
- Date: July 2020
- Lead Investors: Biomedical Advanced Research and Development Authority (BARDA)
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To continue the rapid development and production of a COVID-19 vaccine.
- Amount Raised: $250M
- Date: October 2022
- Lead Investors: DFO Management
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support ongoing research and expand the company's vaccine portfolio.
- Amount Raised: $750M
- Date: March 2024
- Lead Investors: Blackstone Life Sciences
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To develop flu vaccines and diversify revenue streams.
- Amount Raised: $176M
- Date: July 2024
- Lead Investors: U.S. Department of Health & Human Services
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance public health preparedness and response capabilities.
- Amount Raised: $590M
- Date: January 2025
- Lead Investors: U.S. Department of Health & Human Services
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop and distribute mRNA vaccines and therapeutics.
Total Amount Raised: $3.828B. Current Valuation: Not publicly disclosed.
Key Investors
- U.S. Department of Health & Human Services
- Details: The U.S. Department of Health & Human Services (HHS) is a federal agency responsible for protecting the health of all Americans and providing essential human services. It is a major investor in Moderna, particularly in funding vaccine development.
- Investment Focus Areas: Public health, medical research, healthcare services.
- Notable Investments: Moderna, Pfizer, Johnson & Johnson.
- Blackstone Life Sciences
- Details: Blackstone Life Sciences is the life sciences arm of Blackstone Inc., a global investment firm. It focuses on providing capital and strategic support to companies in the life sciences sector.
- Investment Focus Areas: Biotechnology, pharmaceuticals, medical technology.
- Notable Investments: Moderna, Alnylam Pharmaceuticals, Reata Pharmaceuticals.
- DFO Management
- Details: DFO Management is an investment firm that provides capital to high-growth companies. It has a diverse portfolio, including significant investments in the healthcare sector.
- Investment Focus Areas: Healthcare, technology, consumer goods.
- Notable Investments: Moderna, Peloton, SpaceX.
- Biomedical Advanced Research and Development Authority (BARDA)
- Details: BARDA is a U.S. government agency that supports the development and procurement of medical countermeasures against bioterrorism, pandemics, and other public health emergencies. It has been a key investor in Moderna's COVID-19 vaccine development.
- Investment Focus Areas: Vaccines, diagnostics, therapeutics.
- Notable Investments: Moderna, Johnson & Johnson, Regeneron Pharmaceuticals.
- Merck KGaA
- Details: Merck KGaA is a global pharmaceutical and chemical company headquartered in Darmstadt, Germany. It focuses on innovative medicines, life science solutions, and performance materials.
- Investment Focus Areas: Oncology, immunology, neurology.
- Notable Investments: Moderna, Intrexon, F-star Therapeutics.
What's Next for Moderna?
Moderna's future looks promising with a $750 million investment from Blackstone Life Sciences, aimed at developing flu vaccines. This substantial financial backing opens doors for expanding their vaccine portfolio, including potential combination vaccines for influenza and COVID-19. The market for flu vaccines alone is estimated at $7 billion, presenting a significant growth opportunity.
Future fundraising seems likely, given Moderna's innovative approach and the growing interest in mRNA technology. However, challenges such as high R&D expenses and declining COVID-19 vaccine sales could pose hurdles. Effective management of these funds and strategic partnerships will be crucial for sustaining their momentum in the biotech industry.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay's platform to access comprehensive fundraising data on companies like Moderna and gather other critical business insights.
Sign up for free on Clay and start making data-driven decisions today.
